ICON (NASDAQ:ICLR) shares pumped 12% on Wednesday after the Audit Committee wrapped up its probe into the company's accounting practices and controls.

The clinical research organization reported that the investigation revealed inflated revenue for 2023 and 2024, with the impact on each year being below the previously announced upper limit of 2%. Similar issues were identified in 2025, although the impact on revenue was less than in prior years.

ICON is planning to revise its financial results for 2023 and 2024, as well as for the first nine months of 2025. The company confirmed that the accounting issues did not affect clients, operations, or cash flow.

The results aligned with preliminary indications released on February 12, 2026. The company expects to complete its financial reporting and external audit process in the coming weeks, after which it will file its annual report on Form 20-F detailing significant deficiencies and plans to address them.

CEO Barry Balfe announced that the company will provide a broader business update following the completion of the audit process, including details on changes in order portfolio policy, recent business successes, and trends in order cancellations. He noted that while short-term metrics will continue to be impacted by recent market dynamics, the company is encouraged by the improving demand situation.

Balfe emphasized the execution of the company's commercial strategy and stated that ICON's global scale, capabilities, and technology investments position the company for sustainable growth.

#WorldNews2026 #MarketTurbulence

In our group, we've been monitoring dozens of news sites and publications, aiming to present you with only the most interesting updates from the financial markets. Enjoy the read and keep your spirits high! No advice or recommendations here. Every reader will make their own conclusions before making any financial decisions!